| (Values in U.S. Thousands) | Sep, 2025 | Sep, 2024 | Sep, 2023 | Sep, 2022 | Sep, 2021 |
| Sales | 65,320 | 67,640 | 79,200 | 86,160 | 97,070 |
| Sales Growth | -3.43% | -14.60% | -8.08% | -11.24% | -20.74% |
| Net Income | -81,890 | -116,050 | -133,820 | -121,760 | -79,000 |
| Net Income Growth | +29.44% | +13.28% | -9.90% | -54.13% | -118.41% |
Enanta Pharmaceutica (ENTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.
Fiscal Year End Date: 09/30